Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-cash Items (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 10 years of Non-cash Items data on record, last reported at $10.3 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 40.2% year-over-year to $10.3 million; the TTM value through Sep 2025 reached $23.6 million, up 83.82%, while the annual FY2024 figure was $16.8 million, 32.4% up from the prior year.
  • Non-cash Items reached $10.3 million in Q3 2025 per NWBO's latest filing, up from $3.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $17.0 million in Q3 2022 and bottomed at -$143.9 million in Q4 2021.
  • Average Non-cash Items over 5 years is -$6.7 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: plummeted 183.81% in 2023, then skyrocketed 592.87% in 2024.
  • A 5-year view of Non-cash Items shows it stood at -$143.9 million in 2021, then soared by 111.15% to $16.0 million in 2022, then plummeted by 87.29% to $2.0 million in 2023, then skyrocketed by 192.15% to $6.0 million in 2024, then skyrocketed by 72.79% to $10.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $10.3 million in Q3 2025, $3.8 million in Q2 2025, and $3.5 million in Q1 2025.